Third USFDA Form 483 in a Week Hits Dr. Reddy's, This Time at FTO-9 Facility
RDY is trading near its 52-week low of $11.36 (13% above the low).
Summary
Dr. Reddy's received a Form 483 with three observations from the USFDA after a Pre-Approval Inspection of its FTO-9 facility in Visakhapatnam, adding to a string of recent regulatory observations.
Key Events · Product Development and Regulatory · RDY
-
Third Form 483 in a Week
USFDA issued a Form 483 with three observations after a Pre-Approval Inspection of the FTO-9 facility in Visakhapatnam, conducted October 8-9, 2026.
-
Regulatory Pattern Emerging
This follows a Form 483 for FTO-11 on October 8 and two observations at the Mexico API facility in September, indicating a cluster of USFDA compliance issues.
-
Potential Approval Delays
Repeated observations across multiple facilities could delay pending product approvals and require remediation investments.
-
Company Response
Dr. Reddy's states it will address the observations within the stipulated timeline, but no specific remediation plan or cost estimate was disclosed.
Analysis · RDY · Life Sciences
A Form 483 with three observations was issued by the USFDA following a Pre-Approval Inspection of Dr. Reddy's FTO-9 facility in Visakhapatnam, conducted October 8-9, 2026. This marks the third Form 483 disclosed in roughly a week, after observations at FTO-11 on October 8 and at the Mexico API facility in September. The repeated regulatory observations across multiple facilities raise the risk of delayed product approvals and potential remediation costs, though the company states it will address the observations within the stipulated timeline.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $12.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.